Hot Life Science Investor Mandate 3: Corporate Venture Arm of Japanese Biotech Seeking Investments in Europe and US

16 Oct

The corporate investment arm of a Japanese biotechnology company primarily makes early stage investments solely in the Life Sciences. The firm recently raised a new fund in March 2014 and looks to make about 2-3 new investments in the next 12 months. The firm typically allocates USD 1-2 million per round and up to USD 3 million per company. The firm can invest globally, with particular interests in the USA and Europe. The firm is actively seeking new investment opportunities.

The firm seeks to invest in therapeutics, in-vitro diagnostic devices, medical devices and drug discovery platforms. For therapeutics, the firm looks for small molecules, biologics, as well as biosimilars and reformulated drugs. The firm is opportunistic in terms of indications and is particularly interested in orphan indications. The firm will consider products in all stages of development. However, the firm typically invests in products that are in pre-clinical and early-clinical. For medical devices, the firm is also opportunistic in terms of indications; however the firm is only interested in devices with a therapeutic focus.   

The firm will only co-invest with other investors in opportunities outside of Japan. For that reason, the firm prefers opportunities with a syndicate in place. The firm typically requests board observation rights in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: